BDSX Stock - Biodesix, Inc.
Unlock GoAI Insights for BDSX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $71.32M | $49.09M | $38.21M | $54.51M | $45.56M |
| Gross Profit | $55.75M | $36.08M | $24.06M | $23.99M | $23.56M |
| Gross Margin | 78.2% | 73.5% | 63.0% | 44.0% | 51.7% |
| Operating Income | $-34,498,000 | $-41,342,000 | $-50,587,000 | $-40,940,000 | $-22,934,000 |
| Net Income | $-42,931,000 | $-52,146,000 | $-65,447,000 | $-43,159,000 | $-31,350,000 |
| Net Margin | -60.2% | -106.2% | -171.3% | -79.2% | -68.8% |
| EPS | $-6.60 | $-12.80 | $-31.00 | $-31.60 | $-6.48 |
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| May 14th 2025 | William Blair | Downgrade | Market Perform | - |
| September 16th 2024 | Scotiabank | Initiation | Sector Outperform | - |
| July 26th 2024 | Craig Hallum | Initiation | Buy | $3 |
| May 13th 2024 | TD Cowen | Initiation | Buy | $2.8 |
| May 3rd 2024 | Lake Street | Initiation | Buy | $3 |
Earnings History & Surprises
BDSXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 2, 2026 | $-1.05 | — | — | — |
Q4 2025 | Nov 3, 2025 | $-1.60 | $-1.16 | +27.5% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-1.40 | $-1.60 | -14.3% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.08 | $-0.08 | 0.0% | = MET |
Q1 2025 | Mar 3, 2025 | $-0.07 | $-0.06 | +14.3% | ✓ BEAT |
Q4 2024 | Nov 1, 2024 | $-0.08 | $-0.07 | +12.5% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $-0.09 | $-0.08 | +11.1% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-0.15 | $-0.14 | +6.7% | ✓ BEAT |
Q1 2024 | Mar 1, 2024 | $-0.11 | $-0.10 | +9.1% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.15 | $-0.12 | +20.0% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-0.21 | $-0.17 | +19.0% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.26 | $-0.24 | +7.7% | ✓ BEAT |
Q1 2023 | Mar 6, 2023 | $-0.26 | $-0.28 | -7.7% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-0.32 | $-0.34 | -6.3% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-0.47 | $-0.40 | +14.9% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-0.38 | $-0.50 | -31.6% | ✗ MISS |
Q1 2022 | Mar 14, 2022 | $-0.50 | $-0.49 | +2.0% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $-0.50 | $-0.50 | 0.0% | = MET |
Q3 2021 | Aug 10, 2021 | $-0.31 | $-0.41 | -32.3% | ✗ MISS |
Latest News
Biodesix To Present Data On Development Of New Ultra-Sensitive ESR1 Test For Initial Detection And Monitoring Of Mutations In HR+/HER2- Advanced Breast Cancers At SABCS
📈 PositiveBiodesix To Present New Findings On Its On-Market Nodify Lung Tests, With Data Highlighting Importance Of Lung Nodule Risk Classification To Support Early Detection Of Lung Cancer, At 2025 NACLC
📈 PositiveBiodesix shares are trading higher after the company raised FY2025 sales guidance
📈 PositiveBiodesix Q3 EPS $(1.16) Beats $(1.45) Estimate, Sales $21.768M Beat $20.974M Estimate
📈 PositiveBiodesix Raises FY2025 Sales Guidance from $80.000M-$85.000M to $84.000M-$86.000M vs $83.236M Est
📈 PositiveTrading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBiodesix announces one-for-twenty reverse stock split
📉 NegativeBiodesix shares are trading lower after the company announced a 1-for-20 reverse stock split.
📉 NegativeBiodesix Announces 1-For-20 Reverse Stock Split
➖ NeutralBiodesix shares are trading higher after a Form 4 filing showed a director purchased 3,488,372 shares at an average price of $0.43.
📈 PositiveBiodesix shares are trading higher after a Form 4 filing showed a director purchased 3,488,372 shares at an average price of $0.43.
📈 PositiveBiodesix Form 4 Shows Director 3,488,372 @ Avg Price Of $0.43
➖ NeutralFrequently Asked Questions about BDSX
What is BDSX's current stock price?
What is the analyst price target for BDSX?
What sector is Biodesix, Inc. in?
What is BDSX's market cap?
Does BDSX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BDSX for comparison